Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.50)
# 274
Out of 5,154 analysts
28
Total ratings
60%
Success rate
30.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Initiates: Overweight | $40 | $27.05 | +47.87% | 1 | Mar 2, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $13 → $15 | $9.53 | +57.40% | 3 | Feb 27, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $100 → $144 | $99.32 | +44.99% | 2 | Feb 26, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $46.38 | +14.27% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $22.12 | +3.98% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $40.96 | -14.55% | 1 | Feb 11, 2026 | |
| ZYME Zymeworks | Upgrades: Overweight | $25 → $33 | $24.02 | +37.39% | 4 | Dec 12, 2025 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $8 → $11 | $18.05 | -39.06% | 3 | Nov 11, 2025 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $60 | $32.59 | +84.11% | 1 | Oct 31, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $11.05 | +144.34% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $33.05 | +33.13% | 1 | Jun 26, 2025 |
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $27.05
Upside: +47.87%
Relay Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $13 → $15
Current: $9.53
Upside: +57.40%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $100 → $144
Current: $99.32
Upside: +44.99%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $46.38
Upside: +14.27%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $22.12
Upside: +3.98%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $40.96
Upside: -14.55%
Zymeworks
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $24.02
Upside: +37.39%
Bicara Therapeutics
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $18.05
Upside: -39.06%
Immunocore Holdings
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $32.59
Upside: +84.11%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $11.05
Upside: +144.34%
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $33.05
Upside: +33.13%